The rise of cancer vaccines
This issue of our newsletter is supported by Inpart.
Cancer vaccines represent an increasingly important area of biotech in oncology, using the body’s immune system to combat cancer cells. They are broadly categorized into two types: preventive vaccines, designed to avert cancer development by targeting infections that can lead to cancer; and therapeutic vaccines, given to individuals already diagnosed with cancer.
There are also numerous different technologies involved in the development of cancer vaccines. This is because oncology encompasses a vast array of tumors, and while mRNA might be the way to go for melanoma, for example, other tumors might respond differently.
However, as promising as cancer vaccines are, developing them presents multifaceted challenges.
To find out more, read the full article: “The rise of cancer vaccines: A new era in immunotherapy”
A MESSAGE FROM OUR SPONSOR INPART
Antibody Therapy: R&D trends and breakthrough innovations
Interested in high-impact science driving antibody therapy R&D?
Download Inpart’s latest report and take stock of the R&D landscape, the most sought-after early-stage breakthroughs, and the most active institutes and biotechs.
Want to advertise with us? Become our next sponsor.
🔥 More noteworthy articles from this week:
Charcot-Marie-Tooth disease is a group of inherited disorders that cause nerve damage. While treatments exist to help manage some symptoms, there is no cure and patients have various unmet needs. From NMD Pharma’s promising phase 2 trials for NMD670 to promising gene therapies and innovative approaches targeting the disease at the molecular level, here we take a closer look at how science is working to improve patients’ quality of life.
Antisense oligonucleotides are short, single-stranded synthetic fragments of DNA or RNA that bind specifically to the target RNA sequence inside cells and modulate protein expression through several different mechanisms. In recent years, they have gained popularity among drug developers, as they are a highly specific, targeted treatment that can treat a wide range of diseases. In this article, we take a look at six antisense oligonucleotide companies leading the way in this emerging field.
As the new year begins, Donald Trump is set to be sworn in as President of the United States, taking on the nation’s highest office. Alongside him, his chosen leaders for U.S. healthcare could soon assume their roles – pending Senate approval. But not without contention. Some of Trump’s healthcare picks have sparked significant debate. So, what do their appointments signal for the future of healthcare in the U.S.?
Socks and sweaters are great gifts for the winter, but sometimes, a bit of biotech love goes a long way. From glow-in-the-dark mushrooms to do-it-yourself (DIY) biology kits and DNA-shaped utensils to bake goodies, you have this holiday sorted. Here’s a list of biotechnology-themed holiday gifts to get for your friends and family.
Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever. Backed by a multi-million-dollar investment from the Gates Foundation, Sparks adds to Oxitec’s Aedes aegypti technology, called Friendly, which is taking on dengue fever in Brazil. Our guest on this episode of the podcast is the CEO of Oxitec, Grey Frandsen.
The biopharma industry’s pursuit of streamlining complex development and manufacturing workflows is driven by process intensification and integration of automation, continuous processing, and single-use system solutions. This strategy is especially relevant in the current landscape, where recent global health crises are directing the adoption of more versatile and economical manufacturing solutions while adhering to stringent regulatory requirements.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.